IMMVF News 0.7599 Immuno Vaccine Inc (IMMVF)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Immuno Vaccine Inc (IMMVF) 0.7599 $IMMVF

Immunovaccine's DepoVax(TM) Technology Underpins New Experimental Therapy for Cervical, Head and Neck Cancers
Marketwire - Tue Apr 08, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, today announced that its DepoVax(TM) adjuvanting technology will underlie the design of a new cancer vaccine trial that will be conducted by the Dana-Farber Cancer Institute to treat cervical and head and neck cancer.

Immunovaccine Highlights Enhanced Anti-Tumor Activity of Cancer Vaccine Combination Therapies in Presentation at the 2014 AACR Annual Meeting
Marketwire - Mon Apr 07, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, presented positive data from clinical and preclinical vaccine studies, including DPX-Survivac, the company's lead therapeutic cancer vaccine, this weekend at the American Association for Cancer Research (AACR) 2014 Annual Meeting. In a poster presentation, Immunovaccine highlighted results demonstrating that metronomic cyclophosphamide (mCPA), an immune modulating agent, enhanced the immunogenicity of DepoVax(TM)-based vaccines in preclinical cancer models consistent with previously reported Phase I data showing a similar enhancement of DPX-Survivac in patients. Importantly, the animal studies demonstrated the combination therapy's ability to eliminate advanced tumors that could not be treated with vaccine or mCPA alone. Tumors exposed to the combination therapy specifically exhibited an increase in T cell activation markers, suggesting increased immune-mediated anti-tumor activity at the tumor site with the vaccine/mCPA therapy and further supporting the use of the combination therapy in clinical trials.

Immunovaccine to Present Data on Cancer Vaccine Combination Therapies at the 2014 AACR Annual Meeting
Marketwire - Thu Apr 03, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, today announced that data from clinical and preclinical vaccine studies, including DPX-Survivac, the company's lead therapeutic cancer vaccine, will be presented at the American Association for Cancer Research (AACR) 2014 Annual Meeting. The AACR Annual Meeting will be held April 5 - 9, 2014 in San Diego, California.

Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies
Marketwire - Tue Apr 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" (TSX VENTURE: IMV) and Pfenex Inc. ("Pfenex" today announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses.

Immunovaccine Announces 2013 Year-End Results
Marketwire - Mon Mar 17, 7:06AM CDT
Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013.

MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.

Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Immunovaccine Inc names Dr Llew Keltner to board
M2 - Tue Jan 21, 4:13AM CST
Immunotherapy company Immunovaccine Inc (TSX VENTURE:IMV) reported on Monday the addition of Dr Llew Keltner, MD, PhD to its board of directors with immediate effect.

Llew Keltner, US Biotech Industry Adviser, Joins Board of Immunovaccine
Marketwire - Mon Jan 20, 7:08AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately.

Immunovaccine Grants Stock Options
Marketwire - Mon Jan 20, 7:06AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that pursuant to terms and conditions of the Company's stock option plan, it has granted 1,731,500 stock options to employees, consultants, officers and directors. Employees and consultants were granted an aggregate of 457,500 options and officers and directors were granted an aggregate of 1,274,000 options. The options were granted on January 17, 2014 at an exercise price of $0.74. The options for the employees, consultants and directors will vest in three equal tranches at 6, 12, and 18 months from date of grant and the options for the officers will vest in three equal tranches, the first on the date of grant and the others on the first and second anniversary of the date of grant. All options are set to expire five years from the date of grant.

Immunovaccine to Present at 6th Annual Biotech Showcase Conference
Marketwire - Thu Jan 09, 7:05AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that the Company will present at the 6th Annual Biotech Showcase Conference. The conference will take place January 13-15, 2014 at the Parc 55 Wyndham San Francisco Union Square Hotel.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 52

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 182

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 149

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 202

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 111

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 163

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 64

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 0

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
BD&J's Workplace Recognition Meets Los Angeles Growth Test

Updated Category News Views 58

A workplace award is not a verdict from a jury, but it can still tell you where a law firm is putting its money and attention. BD&J Injury Lawyers landed on the Los Angeles Business Journal's 2026 list of most admired law firms to work for, announced November 18. For a personal-injury practice trying to deepen its footing in a brutally crowded Los Angeles market, that is...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading

Top 5 Most Recently Viewed Articles

Delta Air Lines and Taiwan Semiconductor: Earnings Insights

Updated Category News Views 120

Delta Air Lines: Anticipated Earnings Report As we look ahead to the earnings season, all eyes are on Delta Air Lines. Sales projections indicate a modest increase of 0.8%, yet analysts predict a significant downturn of 15.2% in earnings. Despite some downward adjustments from analysts, Delta boasts an impressive history of surprising on earnings. Delta operates multiple...

Continue Reading
Vera Bradley Sees Share Price Decline Amid Revenue Challenges

Updated Category News Views 153

Vera Bradley Experiences Revenue Challenges Amid Market Pressures Vera Bradley, Inc. (NASDAQ: VRA) has recently faced a noteworthy drop in its stock price, which sank by 12.65% in premarket trading. This decline followed the company's second-quarter earnings report that, although it surpassed expectations, revealed that revenue fell short of what analysts had predicted....

Continue Reading
Organon's Q4 Earnings Results: Key Highlights for Investors

Updated Category News Views 188

Understanding Organon's Q4 Earnings Results Organon (NYSE: OGN) has recently shared its earnings report, revealing critical insights that every investor should consider. The report reflects the company's financial health and performance trends over the last quarter, helping stakeholders make informed decisions. Earnings Overview In a notable announcement, Organon reported...

Continue Reading
Expanding Mental Health Services: Ana Deeter Joins Relief

Updated Category News Views 222

Expanding Mental Health Services at Relief Mental Health Relief Mental Health is excited to announce the addition of Ana Deeter, PA-C, to their team at the Northbrook clinic. Deeter, who is a board-certified physician assistant, will enhance the clinic's psychiatric services and offer SPRAVATO® (esketamine) treatment to adults seeking support. A New Specialist for...

Continue Reading
Discover BLUETTI's Cutting-Edge Energy Innovations at CES 2026

Updated Category News Views 245

Revolutionizing Energy Solutions with BLUETTI At this year's CES, BLUETTI, a leader in energy storage solutions, introduced an array of revolutionary products under the theme 'Innovate for All'. These innovations cater to the diverse demands of modern living, providing freedom and resilience for homes, vehicles, and the planet. Key Innovations from BLUETTI As BLUETTI...

Continue Reading